| Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts M Papatheodoridi, E Cholongitas Current pharmaceutical design 24 (38), 4574-4586, 2018 | 169 | 2018 |
| Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease M Papatheodoridi, JB Hiriart, M Lupsor-Platon, F Bronte, J Boursier, ... Journal of Hepatology 74 (5), 1109-1116, 2021 | 150 | 2021 |
| Probability of HBsAg loss after nucleo (s) tide analogue withdrawal depends on HBV genotype and viral antigen levels MJ Sonneveld, SM Chiu, JY Park, SM Brakenhoff, A Kaewdech, WK Seto, ... Journal of hepatology 76 (5), 1042-1050, 2022 | 92 | 2022 |
| Off-Therapy Response After Nucleos (t) ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study) G Hirode, HSJ Choi, CH Chen, TH Su, WK Seto, S Van Hees, ... Gastroenterology 162 (3), 757-771. e4, 2022 | 84 | 2022 |
| Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B GV Papatheodoridis, GN Dalekos, R Idilman, V Sypsa, F Van Boemmel, ... Journal of hepatology 73 (5), 1037-1045, 2020 | 84 | 2020 |
| DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B GV Papatheodoridis, EI Rigopoulou, M Papatheodoridi, K Zachou, ... Antiviral therapy 23 (8), 677-685, 2018 | 83 | 2018 |
| DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B GV Papatheodoridis, EI Rigopoulou, M Papatheodoridi, K Zachou, ... Antiviral therapy 23 (8), 677-685, 2018 | 82 | 2018 |
| Prediction of sustained response after nucleo (s) tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE) MJ Sonneveld, JY Park, A Kaewdech, WK Seto, Y Tanaka, I Carey, ... Clinical Gastroenterology and Hepatology 20 (4), e784-e793, 2022 | 67 | 2022 |
| Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis E Cholongitas, I Pavlopoulou, M Papatheodoridi, GE Markakis, E Bouras, ... Annals of Gastroenterology 34 (3), 404, 2021 | 59 | 2021 |
| Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B T Voulgaris, M Papatheodoridi, P Lampertico, GV Papatheodoridis Liver International 40 (3), 484-495, 2020 | 51 | 2020 |
| Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B M Papatheodoridi, E Hadziyannis, F Berby, K Zachou, B Testoni, ... Journal of Viral Hepatitis 27 (2), 118-126, 2020 | 44 | 2020 |
| Risk of HBV reactivation during therapies for HCC: A systematic review M Papatheodoridi, M Tampaki, AS Lok, GV Papatheodoridis Hepatology 75 (5), 1257-1274, 2022 | 32 | 2022 |
| Systematic review and meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease E Tsompanaki, K Thanapirom, M Papatheodoridi, P Parikh, YC de Lima, ... Clinical Gastroenterology and Hepatology 21 (6), 1462-1474. e24, 2023 | 28 | 2023 |
| Can we stop nucleoside analogues before HB sAg loss? M Papatheodoridi, G Papatheodoridis Journal of Viral Hepatitis 26 (8), 936-941, 2019 | 28 | 2019 |
| Risk scores for hepatocellular carcinoma in chronic hepatitis B: a promise for precision medicine GV Papatheodoridis, T Voulgaris, M Papatheodoridi, WR Kim Hepatology 72 (6), 2197-2205, 2020 | 23 | 2020 |
| Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study A Goyale, A Jain, C Smith, M Papatheodoridi, MG Misas, D Roccarina, ... PloS one 16 (11), e0260313, 2021 | 21 | 2021 |
| Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer K Thanapirom, E Caon, M Papatheodoridi, L Frenguelli, W Al-Akkad, ... Cancers 13 (19), 4936, 2021 | 19 | 2021 |
| Emerging Diagnostic Tools to Decide When to Discontinue Nucleos (t) ide Analogues in Chronic Hepatitis B M Papatheodoridi, G Papatheodoridis Cells 9 (2), 493, 2020 | 19 | 2020 |
| Is hepatitis delta underestimated? M Papatheodoridi, GV Papatheodoridis Liver International 41, 38-44, 2021 | 16 | 2021 |
| Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B HSJ Choi, G Hirode, CH Chen, TH Su, WK Seto, S Van Hees, ... Clinical Gastroenterology and Hepatology 21 (6), 1513-1522. e4, 2023 | 13 | 2023 |
